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Abnormal production of reactive oxygen species (ROS) induces tissue damage and superoxide dismutase (SOD)
that converts superoxide radicals to hydrogen peroxide functions as defense against ROS. Cu/Zn SOD
administration has been shown to be effective for various ﬁbrotic conditions by inhibiting the ﬁbrogenic effects
of ROS. We hypothesized that autoimmune background in localized scleroderma induced anti-Cu/Zn SOD
autoantibodies that inhibited SOD activity and thereby contributed to ﬁbrosis by increasing ROS. ELISA using
human puriﬁed Cu/Zn SOD revealed that IgG or IgM anti-Cu/Zn SOD Ab was detected in the serum of 89% of
localized scleroderma patients, especially 100% of patients with generalized morphea, the severest form of
localized scleroderma, but was positive only in the serum of less than 15% of patients with other autoimmune
disorders, including systemic sclerosis, systemic lupus erythematosus, dermatomyositis, and autoimmune
bullous disorders. The immunoblotting analysis conﬁrmed the presence of IgG anti-Cu/Zn SOD Ab in sera from
localized scleroderma patients. Remarkably, anti-Cu/Zn SOD autoantibody could inhibit Cu/Zn SOD enzymatic
activity. Collectively, these results indicate that anti-Cu/Zn SOD Ab is a novel, major autoantibody in localized
scleroderma, and also suggest that the autoantibody may play a role in the development of ﬁbrosis by directly
inhibiting SOD activity.
Key words: autoimmunity/fibrosis/reactive oxygen species
J Invest Dermatol 122:594 –601, 2004
Scleroderma is a chronic connective tissue disorder with an
autoimmune background, and is divided into two types:
localized scleroderma and systemic sclerosis (SSc). In
localized scleroderma, fibrosis is limited to the skin and
the subcutaneous tissues beneath the cutaneous lesions.
This disease differs from SSc in that it is not accompanied
by Raynaud’s phenomenon, acrosclerosis, and internal
organ involvement (Jablonska and Rodnan, 1979). There-
fore, the prognosis for patients with localized scleroderma is
good; however, the disfigurement and deformities of the
extremities and face resulting from deep fibrosis markedly
impair the quality of life (Jablonska and Rodnan, 1979).
Morphologically, localized scleroderma is classified into
three subsets: morphea, linear scleroderma, and general-
ized morphea (Sato et al, 1994b). Morphea is usually
characterized by one or a few circumscribed sclerotic
plaques with an ivory-colored center and a surrounding
violaceous halo. Linear scleroderma appears in a linear,
band-like distribution, and often involves the muscle and
bone underlying the skin lesions. Generalized morphea is a
severe form of localized scleroderma characterized by
widespread skin involvement with multiple lesions.
Both localized scleroderma and SSc exhibit auto-
immunity as a central feature of the diseases. Localized
scleroderma, especially generalized morphea, is accompa-
nied by the presence of various autoantibodies, such as
antinuclear antibody (Ab), antihistone Ab, anti-single-
stranded DNA (ssDNA) Ab, anti-phospholipid Ab, rheuma-
toid factor, and lupus erythematosus cell phenomenon
(Falanga et al, 1986, 1987; Sato et al, 1993, 1994a, 2003).
Similarly, SSc exhibits the production of autoantibodies
against various intracellular components, such as DNA topo-
isomerase I, centromere, RNA polymerases, and U3RNP
(Okano, 1996). Although localized scleroderma and SSc
share some autoantibody specificities such as antihistone
Ab, anti-ssDNA Ab, and rheumatoid factor, autoantibodies
specific to SSc, such as anti-DNA topoisomerase I and
anticentromere Abs, are absent in localized scleroderma
with few exceptions (Sato et al, 1993). Thus, although both
SSc and localized scleroderma show cutaneous fibrosis,
autoantibody specificities associated with these diseases
are different.
Life in an aerobic environment is associated with the
production of superoxide radicals (O2 ) that can lead to the
formation of various reactive oxygen species (ROS) (Noor
et al, 2002; Zelko et al, 2002). While physiological levels of
ROS are beneficial to prevent invading pathogens, an
unbalanced, elevated level of ROS induces tissue damage,
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resulting in the development of various disorders, such as
inflammation, arthritis, diabetes, atherosclerosis, hyperten-
sion, and premature aging. The first and most important line
of defense against the damaging effects of ROS is the
superoxide dismutase (SOD) that converts O2 to hydrogen
peroxide. There are three forms of the enzyme in mammals:
a cytosolic form (Cu/Zn SOD or SOD1), a mitochondrial
form (Mn SOD or SOD2), and an extracellular form (EC SOD
or SOD3). The Cu/Zn SOD is a ubiquitous and constitutively
expressed enzyme that is dependent upon copper and zinc
ions for activity and accounts for 75% of total SOD activity
(Marklund, 1984; Noor et al, 2002; Zelko et al, 2002).
A recent study has shown that ROS production is
increased in dermal fibroblasts by stimulation with cyto-
kines and induces fibroblast proliferation and expression of
type I collagen genes in SSc-derived fibroblasts (Sambo
et al, 2001). Furthermore, cutaneous infiltration of inflam-
matory cells, especially macrophages, is a potential source
of ROS in localized scleroderma and SSc (Speer et al,
1984). Thus, the increased ROS production may be related
to skin fibrosis in localized scleroderma and SSc. On the
other hand, exogenous administration of Cu/Zn SOD has
been shown to be effective for various fibrotic conditions,
including radiation-induced cutaneous fibrosis (Delanian
et al, 1994; Lefaix et al, 1996), bleomycin-induced fibrosis of
the lung and skin (Yamazaki et al, 1997; Yamamoto et al,
1999), and cholestasis-induced liver fibrosis (Zhong et al,
2002). Furthermore, autoantibodies against Mn SOD have
been detected in patients with acute Epstein–Barr virus
infection (Ritter et al, 1994; Semrau et al, 1998), while
autoantibodies to Cu/Zn SOD are present in patients with
autoimmune hepatitis (Miyata et al, 1995). Therefore, we
hypothesized that autoimmune background in localized
scleroderma and SSc induced anti-Cu/Zn SOD autoanti-
bodies that inhibited Cu/Zn SOD activity and thereby
contributed to fibrosis by increasing ROS levels. To test
this possibility, the presence or levels of autoantibodies to
Cu/Zn SOD, their clinical correlation, and their functional
significance were investigated in the current study. In this
study, autoantibodies against Cu/Zn SOD were significantly
elevated in patients with localized scleroderma, but not in
those with SSc, compared with normal controls. The results
of this study suggest that anti-Cu/Zn SOD autoantibodies
detected in patients with localized scleroderma play a role
in the development of fibrosis by directly inhibiting Cu/Zn
SOD activity.
Results
Anti-Cu/Zn SOD autoantibody levels by ELISA were
elevated in localized scleroderma The presence and
levels of anti-Cu/Zn SOD autoantibodies in serum samples
from patients with autoimmune diseases and normal
controls were assessed by ELISA. Patients with localized
scleroderma exhibited significantly higher anti-Cu/Zn SOD
Ab levels of both IgG (Fig 1a) and IgM (Fig 1b) than those
found in normal controls (po0.0001). By contrast, patients
with SSc, SLE, DM, or PV/PF/BP had normal IgG and IgM
anti-Cu/Zn SOD Ab levels; therefore, both IgG and IgM
levels of anti-Cu/Zn SOD Ab in patients with localized
scleroderma were significantly increased compared with
those with SSc, SLE, DM, or PV/PF/BP (po0.0001 for IgG
isotype and po0.0005 for IgM isotype). There were no
significant differences in IgG and IgM anti-Cu/Zn SOD Ab
levels between patients with SSc, SLE, DM, or PV/PF/BP.
IgG anti-Cu/Zn SOD Ab levels in patients with general-
ized morphea, linear scleroderma, or morphea were
significantly higher than those found in normal controls
(po0.0001, Fig 2), but were comparable among the three
subsets of localized scleroderma. Similarly, IgM anti-Cu/Zn
SOD Ab levels were significantly elevated in patients
with generalized morphea (po0.0001), linear scleroderma
(po0.001), or morphea (po0.01) relative to normal controls.
Patients with generalized morphea had significantly higher
IgM anti-SOD levels than those with morphea (po0.05),
while there was no significant difference in IgM anti-Cu/Zn
SOD Ab levels between patients with generalized morphea
and those with linear scleroderma. IgG anti-Cu/Zn SOD Ab
levels did not significantly correlate with IgM anti-Cu/Zn
Figure 1
Anti-Cu/Zn SOD autoantibody levels
were elevated in serum samples from
patients with localized scleroderma
(LSc). Anti-Cu/Zn SOD Ab levels were
examined in serum samples from patients
with LSc, SSc, SLE, DM, or PV/PF/BP and
normal controls (CTL). Anti-Cu/Zn SOD Ab
levels as the relative optical density (OD)
were determined by ELISA using human
purified Cu/Zn SOD. The short bars
indicate the mean values in each group.
Broken lines indicate the cut-off values
(meanþ3SD of the control samples).
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SOD Ab levels in patients with localized scleroderma (data
not shown). Furthermore, IgG and IgM anti-Cu/Zn SOD Ab
levels did not correlate with serum total IgG and IgM levels,
respectively (data not shown). Thus, IgG and IgM anti-Cu/
Zn SOD autoantibody levels were increased in localized
scleroderma, but not in other autoimmune diseases,
including SSc, SLE, DM, and PV/PF/BP.
High prevalence of anti-Cu/Zn SOD Ab in localized
scleroderma Absorbance values higher than the mean
þ3SD (0.75 for IgG anti-Cu/Zn SOD Ab and 0.58 for IgM
anti-Cu/Zn SOD Ab) of the control serum samples were
considered positive in this study (Fig 1). In total patients with
localized scleroderma, IgG or IgM anti-Cu/Zn SOD Ab was
found in 89% (Table I). IgG isotype of this autoantibody
(87%) was more frequently detected than IgM isotype
(48%). By contrast, IgG or IgM anti-Cu/Zn SOD Ab was
detected only in 8% of patients with SSc, 15% of those with
SLE, 13% of those with DM, and 4% of those with PV/PF/
BP. IgM anti-Cu/Zn SOD Ab was detected in 5% of healthy
controls, while IgG anti-Cu/Zn SOD Ab was not detected in
any healthy individuals. In the subgroups of localized
scleroderma, IgG or IgM anti-Cu/Zn SOD Ab was present
in 100% of patients with generalized morphea, 82% of
those with linear scleroderma, and 91% of those with
morphea. Thus, anti-Cu/Zn SOD Ab was detected in
 90% of localized scleroderma patients with 100% of
generalized morphea patients.
IgM anti-Cu/Zn SOD Ab correlated with other autoanti-
bodies and disease severity in localized scleroderma
Since there were only six localized scleroderma patients
negative for IgG anti-Cu/Zn SOD Ab versus 40 patients
positive for this autoantibody, the presence of IgG anti-
Cu/Zn SOD Ab was not significantly associated with the
presence or absence of any serological and clinical
parameters, except for the presence of antinuclear Abs
(27 of 40, 68% of patients with this Ab vs one of six, 17% of
patients without this Ab, po0.05). Localized scleroderma
patients with IgM anti-Cu/Zn SOD Ab correlated signifi-
cantly with the presence of antinuclear Abs (po0.05) or
rheumatoid factor (po0.01), IgG antihistone Ab levels
(po0.05), IgM antihistone Ab levels (po0.01), or IgG anti-
ssDNA levels (po0.01; Table II). The age at onset was
Figure 2
IgG anti-Cu/Zn SOD Ab levels were
similar in the three subgroups of loca-
lized scleroderma while IgM anti-Cu/Zn
SOD Ab levels were elevated in gen-
eralized morphea relative to morphea.
Anti-Cu/Zn SOD Ab levels as the relative
optical density (OD) were measured by
ELISA in serum samples from patients
with generalized morphea (GM), linear
scleroderma (Linear Scl.), or morphea
and normal controls (CTL). Broken lines
indicate the cut-off values (meanþ 3SD of
the control samples) and the short bars
indicate the mean values in each group.
Table I. Frequency of anti-Cu/Zn SOD Ab in autoimmune
diseases and normal controlsa
Anti-Cu/Zn SOD Ab
IgG IgM IgG or IgM
LScb (n¼46) 40 (87) 22 (48) 41 (89)
GM (n¼13) 12 (92) 11 (85) 13 (100)
Linear Scl. (n¼ 22) 18 (82) 8 (36) 18 (82)
Morphea (n¼11) 10 (91) 3 (27) 10 (91)
SSc (n¼75) 2 (3) 4 (5) 6 (8)
SLE (n¼39) 2 (5) 4 (10) 6 (15)
DM (n¼ 24) 2 (8) 1 (4) 3 (13)
PV/PF/BP (n¼ 25) 0 (0) 1 (4) 1 (4)
Normal (n¼ 65) 0 (0) 3 (5) 3 (5)
aValues are the number (%) of patients with anti-Cu/Zn SOD Ab. IgG
and IgM anti-Cu/Zn SOD Abs were determined by ELISA using anti-
human IgG and IgM Abs as secondary Abs, respectively.
bLSc, localized scleroderma; GM, generalized morphea; Linear Scl.,
linear scleroderma.
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significantly younger in patients with IgM anti-Cu/Zn SOD
Ab than those without IgM anti-Cu/Zn SOD Ab (po0.05).
The number of plaque lesions and involved body areas were
significantly greater in patients with IgM anti-Cu/Zn SOD Ab
than those without IgM anti-Cu/Zn SOD Ab (po0.05). Thus,
IgM anti-Cu/Zn SOD Ab levels correlated with the disease
severity as well as the presence or levels of other auto-
antibodies in patients with localized scleroderma.
The presence of anti-Cu/Zn SOD Ab in localized sclero-
derma was conﬁrmed by immunoblotting The presence
of anti-Cu/Zn SOD Ab was further evaluated by immuno-
blotting analysis using human purified Cu/Zn SOD. Serum
samples from localized scleroderma patients positive for
IgG anti-Cu/Zn SOD Ab by ELISA exhibited reactivity with
SOD (32 kDa) by immunoblotting (Fig 3, lanes 1–5). By
contrast, serum samples from SSc patients negative for IgG
anti-Cu/Zn SOD Ab by ELISA did not react with Cu/Zn SOD
(lane 6). Similarly, any reactivity with Cu/Zn SOD was not
observed using serum samples from patients with either
localized scleroderma or SLE negative for IgG anti-Cu/Zn
SOD Ab by ELISA (data not shown). Furthermore, serum
samples from healthy individuals did not react with Cu/Zn
SOD (lane 7). Thus, the presence of anti-Cu/Zn SOD
autoantibody in patients with localized scleroderma was
confirmed by immunoblotting analysis.
Anti-Cu/Zn SOD Ab in localized scleroderma inhibited
SOD activity To determine the functional relevance of anti-
Cu/Zn SOD autoantibody, it was assessed whether anti-Cu/
Zn SOD Ab was able to inhibit SOD activity. SOD activity
was determined using a specific spectrophotometric assay,
in which SOD activity was assessed by the SOD-induced
increase in the autoxidation rates of 5,6,6a,11b-tetrahydro-
3,9,10-trihydroxybenzo[c]fluorine. SOD activity was not
inhibited by IgG isolated from healthy individuals (Fig 4).
By contrast, IgG isolated from serum samples of localized
scleroderma patients positive for IgG anti-Cu/Zn SOD Ab by
ELISA significantly inhibited SOD activity by 59% compared
with normal control (po0.001). This inhibitory activity was
not due to the presence of autoantibodies other than anti-
Cu/Zn SOD Ab since SOD activity was not inhibited by IgG
isolated from serum samples that contained autoantibodies
against ssDNA or histone, but not IgG anti-Cu/Zn SOD Ab.
Similarly, the inhibition of SOD activity was not detected
using serum samples from SSc or SLE patients without IgG
anti-Cu/Zn SOD Ab by ELISA (data not shown). Thus, IgG
anti-Cu/Zn SOD Ab from patients with localized scleroder-
ma was able to inhibit SOD enzymatic activity.
Discussion
In the current study, IgG or IgM anti-Cu/Zn SOD Ab was
detected in the serum of 89% of patients with localized
scleroderma, especially 100% of patients with generalized
morphea, the severest form of localized scleroderma (Figs 1
and 2 and Table I). By contrast, anti-Cu/Zn SOD Ab was
positive at much lower frequency in the serum of SSc (8%)
as well as SLE (15%), DM (13%), and autoimmune bullous
disorders (4%). Although localized scleroderma and SSc
Table II. Clinical and serological features of patients with
localized scleroderma positive for IgM anti-Cu/Zn SOD Aba
IgM anti-Cu/Zn
SOD
Abþ (n¼ 22)
IgM anti-Cu/Zn
SOD
Ab(n¼ 24)
Serological
Antinuclear Ab 19 (86) 9 (38)
IgG antihistone Ab (OD)b 0.85  0.21 0.66  0.28
IgM antihistone Ab (OD) 0.76  0.20 0.42  0.13
IgG anti-ssDNA Ab (OD) 0.63  0.23 0.43  0.15
Rheumatoid factor 13 (59) 1 (4)
Clinical
Sex (male/female) 5/17 7/17
Age at onset (y) 16  14 27  17
Disease duration (y) 3.7  4.4 6.5  9.3
No. of linear lesions 1.1  1.1 0.8  0.8
No. of plaque lesions 2.8  2.3 1.7  3.0
Total no. of lesions 4.0  2.8 2.5  3.1
No. of involved
body areas
2.3  1.5 1.8  1.6
Muscle involvement 7 (32) 2 (8)
aValues are mean  SD. Unless otherwise indicated, values are the
number (%) of positive patients. IgM anti-Cu/Zn SOD Abs were
determined by ELISA using anti-human IgM Abs as secondary Abs.
bAntihistone Ab and anti-ssDNA Ab levels as the relative optical density
(OD) were determined by specific ELISA.
po0.05 and po0.01 versus patients without IgM anti-Cu/Zn SOD
Ab.
Figure3
The presence of IgG anti-Cu/Zn SOD Ab in sera from patients with
localized scleroderma was confirmed by immunoblotting. Repre-
sentative immunoblotting of human purified Cu/Zn SOD with sera from
patients or a normal control is shown. Lanes 1–5, serum samples from
patients with localized scleroderma positive for IgG anti-Cu/Zn SOD Ab
by ELISA; lane 6, a serum sample from an SSc patient negative for IgG
anti-Cu/Zn SOD Ab by ELISA; lane 7, a normal human serum; lane 8,
colloidal gold-stained Cu/Zn SOD (32 kDa). Makers for molecular
weights (kDa) are shown to the left. The results represent those
obtained with 10 serum samples of patients with localized scleroderma
positive for IgG anti-Cu/Zn SOD Ab by ELISA, 15 serum samples of
patients with either localized scleroderma, SSc, or SLE negative for IgG
anti-Cu/Zn SOD Ab by ELISA, and 10 serum samples from healthy
individuals.
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share skin fibrosis and autoimmunity (Sato et al, 1993;
Okano, 1996), the production of anti-Cu/Zn SOD autoanti-
body is highly specific to localized scleroderma, indicating
that autoimmune reactions are distinct between these two
diseases. The presence of IgG anti-Cu/Zn SOD Ab in sera
from patients with localized scleroderma was further
confirmed by the immunoblotting analysis (Fig 3). The
presence of IgM anti-Cu/Zn SOD Ab was associated with
the greater number of plaque-type sclerotic lesions, the
wider distribution of lesions, and the production of other
autoantibodies including antinuclear Ab, antihistone Ab,
anti-ssDNA Ab, and rheumatoid factor in patients with
localized scleroderma (Table II). Remarkably, the anti-Cu/Zn
SOD autoantibodies were able to inhibit Cu/Zn SOD
enzymatic activity (Fig 4). Collectively, the results of the
present study indicate that the anti-Cu/Zn SOD Ab is a
novel, major autoantibody with potential functional signifi-
cance in localized scleroderma.
Accumulating evidence suggests that ROS may directly
induce collagen gene expression via effects on lipid pero-
xidation (Chojkier et al, 1989; Ruiz et al, 2000). Furthermore,
many recent reports have shown that Cu/Zn SOD reduces
fibrosis by inhibiting the production of ROS. Lecithinized
Cu/Zn SOD is effective for bleomycin-induced fibrosis of
both lung and skin (Yamazaki et al, 1997; Yamamoto et al,
1999). Gene delivery of Cu/Zn SOD attenuates experimental
cholestasis-induced liver fibrosis in the rat (Zhong et al,
2002). Furthermore, administration with liposomal Cu/Zn
SOD significantly reduces radiation-induced skin fibrosis of
human and pig (Delanian et al, 1994; Lefaix et al, 1996). In
vitro analysis using cultured human skin fibroblasts from
radiation-induced fibrosis has revealed that Cu/Zn SOD
treatment significantly reduces the expression levels of
tissue inhibitor of metalloproteinases (TIMP) and transform-
ing growth factor (TGF)-b (Delanian et al, 2001). Similar
results are obtained using the three-dimensional model of
skin fibrosis that is reconstituted by primary fibroblasts and
keratinocytes from pig skin of radiation-induced fibrosis
(Vozenin-Brotons et al, 2001). TIMP can increase extra-
cellular matrix deposition by inhibiting the activity of matrix
metalloproteinases, a family of zinc-dependent endopepti-
dases that collectively can digest all extracellular matrix
components (Gomez et al, 1997). In addition, TGF-b is a
major fibrogenic growth factor since it not only stimulates
matrix synthesis but also controls virtually all fibroblast
function relevant to fibrosis, including proliferation, chemo-
taxis, and differentiation (Varga, 2002). These findings
suggest that, in a model of radiation-induced skin fibrosis,
Cu/Zn SOD diminishes fibrosis possibly by reducing the
expression of TIMP and TGF-b. In the affected skin from
patients with localized scleroderma, increased expression
of TIMP, TGF-b, and TGF-b receptors on dermal fibroblasts
has been reported (Higley et al, 1994; Mattila et al, 1998;
Kubo et al, 2001). Furthermore, anti-Cu/Zn SOD Ab in sera
from patients with localized scleroderma was able to inhibit
Cu/Zn SOD activity (Fig 4), which may result in increased
expression of TIMP and TGF-b. Collectively, the results of
this study suggest that anti-Cu/Zn SOD autoantibodies can
inhibit the antifibrogenic activity of Cu/Zn SOD in localized
scleroderma.
Unlike SSc, localized scleroderma is characterized by
the scattered sclerotic lesions that do not involve the whole
body even if the lesions are multiple. Cu/Zn SOD, however,
is a ubiquitous antioxidant enzyme that is expressed in all
cell types (Noor et al, 2002; Zelko et al, 2002). Therefore, it
remains unknown as to why systemic production of auto-
antibodies against Cu/Zn SOD in localized scleroderma
affects only partial body areas, given that the autoantibo-
dies can block the antifibrogenic activity of Cu/Zn SOD. It
has been reported that some causes of familial amyotrophic
lateral sclerosis are associated with mutations in the Cu/Zn
SOD gene, many of which reduce the total activity and half-
life of the enzyme (Rosen et al, 1993; Noor et al, 2002). The
role of the mutated Cu/Zn SOD gene, however, as a cause
of familial amyotrophic lateral sclerosis remains unknown
since some lines of transgenic mice overexpressing mutant
Cu/Zn SOD develop motor neuron disease, despite having
elevated Cu/Zn SOD activity (Gurney et al, 1994; Noor et al,
2002). Furthermore, Cu/Zn SOD-deficient mice develop
normally and show no overt motor deficits (Reaume et al,
1996). Interestingly, Cu/Zn SOD-deficient mice exhibit
marked vulnerability to motor neuron loss only after axonal
injury, indicating that Cu/Zn SOD is not necessary for
normal motor neuron development and function, and that
an important function of Cu/Zn SOD is the protection of
various cell types from the oxidative burden imposed by
injury (Reaume et al, 1996). It has been reported that various
physical injury, including trauma, radiation, burn, local
corticosteroid injection, surgical procedures, immunization,
and varicella infection, is a provoking factor in localized
scleroderma (Trattner et al, 1991; Komocsi et al, 2000).
Therefore, it may be possible that physical skin injury
Figure 4
IgG anti-Cu/Zn SOD Ab from patients with localized scleroderma
inhibited SOD activity. IgG was purified from serum samples of
localized scleroderma patients positive for IgG anti-Cu/Zn SOD Ab by
ELISA (anti-SOD Ab (þ ); n¼ 10), serum samples of localized
scleroderma negative for IgG anti-Cu/Zn SOD Ab by ELISA (anti-SOD
Ab (); n¼5), and serum samples from healthy individuals (CTL;
n¼10). Purified IgG was incubated with Cu/Zn SOD and SOD activity
was determined using a specific spectrophotometric assay, in which
SOD activity was assessed by the SOD-induced increase in the
autoxidation rates of 5,6,6a,11b-tetrahydro-3,9,10-trihydroxybenzo[c]-
fluorine. SOD activity incubated with purified IgG is shown as a
percentage of untreated SOD that was defined as 100%. The
histogram shows the mean  SD.
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induces the local production of potentially fibrogenic ROS,
the activity of which may be enhanced by anti-Cu/Zn SOD
autoantibodies in localized scleroderma.
IgM autoantibodies to Mn SOD have been detected in
patients with acute Epstein–Barr virus infection (Ritter et al,
1994; Semrau et al, 1998). This anti-Mn SOD Ab can inhibit
Mn SOD enzymatic activity and their levels coincide with the
clinical symptoms, suggesting that anti-Mn SOD Ab
contributes to tissue injury (Ritter et al, 1994). Thus, anti-
SOD Ab may be generated by environmental stimuli, such
as viral infection. Although none of the localized scleroder-
ma patients examined in this study had a recent history of
infection, the observation that localized scleroderma pa-
tients with IgM anti-Cu/Zn SOD Ab exhibited significantly
younger age at onset compared with those without this Ab
may be related to virus-induced production of this autoanti-
body (Table II). Consistently, it has been suggested that
autoimmunity may be environmentally driven in localized
scleroderma since localized scleroderma, especially gen-
eralized morphea, and drug-induced lupus share specifi-
cities of autoantibodies (Sato et al, 1993, 2003). Although
the mechanisms for the autoantibody production in loca-
lized scleroderma remain unknown, the high prevalence of
anti-Cu/Zn SOD Abs and their functional inhibition of Cu/Zn
SOD may be an important clue for understanding the
pathogenesis of this disease.
Materials and Methods
Serum samples Serum samples were obtained from 46 Japanese
patients with localized scleroderma (12 males and 34 females).
Patients were classified into the following three subgroups as
described previously (Sato et al, 1994b): 13 patients with general-
ized morphea (two males and 11 females), 22 patients with linear
scleroderma (six males and 16 females), and 11 patients with
morphea (four males and seven females). The age of patients with
localized scleroderma (mean  SD) was 27  17 y (generalized
morphea, 24  19; linear scleroderma, 22  13; morphea, 40  17
y). The disease duration of patients with localized scleroderma was
5.1  7.4 y (generalized morphea, 3.2  2.8; linear scleroderma,
6.9  9.4; morphea, 3.8  6.0 y). None of the localized sclero-
derma patients were treated with steroids or immunosuppressive
therapy. None of the patients had a recent history of infection and
abnormal liver function. The number of sclerotic lesions more than
3 cm in diameter was counted in each patient with localized
scleroderma when the serum samples were obtained. The sclerotic
lesions were morphologically classified into plaque and linear
lesions. We divided the whole body into the following seven areas:
head and neck; right upper extremity; left upper extremity; ante-
rior trunk; posterior trunk; right lower extremity; and left lower
extremity. Then we counted the number of involved areas as
described previously (Sato et al, 1994b).
Serum samples from 75 patients with SSc who fulfilled the
criteria proposed by the American College of Rheumatology
(Subcommittee for Scleroderma Criteria of the American Rheuma-
tism Association Diagnostic and Therapeutic Criteria Committee,
1980) were also examined in this study. These patients were
grouped according to LeRoy et al (1988): 40 patients (two males
and 38 females) had limited cutaneous SSc and 35 patients (five
males and 30 females) had diffuse cutaneous SSc. The age of
patients with SSc was 50  15 y (limited cutaneous SSc, 54  11;
diffuse cutaneous SSc, 45  18 y). The disease duration of
patients with limited cutaneous SSc and diffuse cutaneous SSc
was 8.3  8.0 and 5.9  8.0 y, respectively. None of the SSc
patients were treated with steroids, D-penicillamine, or immuno-
suppressive therapy. In this study, 39 patients with systemic lupus
erythematosus (SLE; five males and 34 females; age 36  12 y), 24
patients with dermatomyositis (DM; five males and 19 females; age
42  25 y), and 25 patients with autoimmune bullous diseases
(nine males and 16 females; age 43  10 y) including pemphigus
vulgaris (PV; n¼ 11)/pemphigus foliaceus (PF; n¼ 5)/bullous
pemphigoid (BP; n¼ 9) were also examined as disease control.
SLE and DM were diagnosed according to the criteria proposed by
the American College of Rheumatology (Tan et al, 1982) and the
criteria proposed by Bohan and Peter (1975a,b), respectively.
Sixty-five healthy Japanese people (17 males and 48 females; age
29  14 y) that were age- and sex-matched to patients with
localized scleroderma were used as normal controls. Fresh venous
blood samples were centrifuged shortly after clot formation. All
samples were stored at 701C prior to use. All investigations were
performed after approval by the Kanazawa University Graduate
School of Medical Science and according to the Declaration of
Helsinki principles.
ELISA for anti-Cu/Zn SOD Ab ELISA for anti-Cu/Zn SOD Ab was
performed as previously described (Sato et al, 1993). Briefly, 96-
well plates (EIA/RIA plate, Coster, Cambridge, Massachussets)
were coated with Cu/Zn SOD purified from human red blood cells
(1 mg per mL; Sigma-Aldrich, St Louis, Missouri) at 41C overnight.
The wells were blocked with 2% bovine serum albumin and 1%
gelatin in Tris-buffered saline for 1 h at 371C. The serum samples
(100 mL) diluted to 1:100 were added to triplicate wells for 90 min
at 201C. After washing four times, the bound antibodies were
detected with alkaline phosphatase-conjugated goat anti-human
IgG or IgM Abs (Cappel, Durham, North Carolina) using p-nitro-
phenyl phosphate (Sigma-Aldrich) as substrate. The optical density
of the wells was subsequently determined. Absorbance values
greater than the mean þ 3SD of normal controls were considered
positive in this study.
Immunoblotting analysis Cu/Zn SOD (5 mg per lane; Sigma-
Aldrich) was subjected to electrophoresis on 10%–20% gradient
sodium dodecyl sulfate-polyacrylamide slab gels. The proteins
were electrotransferred from the gels to nitrocellulose sheets for
immunoblotting analysis. The nitrocellulose sheets were cut into
strips and incubated overnight with serum samples diluted to 1:50.
The strips were then incubated for 1.5 h with alkaline phosphatase-
conjugated goat anti-human IgG Ab (Cappel), and color was
developed with 5-bromo-4-chloro-3-indolyl phosphate and nitro
blue tetrazolium (Sigma-Aldrich). Ten localized scleroderma pa-
tients positive for IgG anti-Cu/Zn SOD Ab by ELISA, 15 patients
with either localized scleroderma, SSc, or SLE negative for IgG
anti-Cu/Zn SOD Ab by ELISA, and 10 healthy individuals were
evaluated.
SOD activity assay IgG was purified from serum samples using
magnetic beads coated with recombinant protein G covalently
coupled to the surface (Dynal, Lake Success, New York). The final
IgG concentration was measured by a spectrophotometer (Gene
Quant II, Amersham Biosciences, Piscataway, New Jersey). SOD
(5 mg) was incubated with purified IgG (40 mg) for 20 min at 251C.
SOD activity was determined by a specific spectrophotometric
assay kit (Oxis Health Products, Portland, Oregon), according to
the manufacturer’s protocol. Briefly, SOD activity was assessed by
the SOD-mediated increase in the rate of autoxidation of
5,6,6a,11b-tetrahydro-3,9,10-trihydroxybenzo[c]fluorene at pH 8.8
to yield a chromophore with maximum absorbance at 525 nm. The
SOD activity was determined from the ratio of the autoxidation
rates in the presence and absence of SOD. Ten localized
scleroderma patients positive for IgG anti-Cu/Zn SOD Ab by
ELISA, 15 patients with either localized scleroderma, SSc, or SLE
negative for IgG anti-Cu/Zn SOD Ab by ELISA, and 10 healthy
individuals were assessed.
Detection of antinuclear Ab, antihistone Ab, anti-ssDNA Ab,
and rheumatoid factor Antinuclear Ab was assessed by indirect
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immunofluorescence staining using HEp-2 substrate cells (MBL,
Nagoya, Japan) as described (Sato et al, 1993). Acetone-fixed
HEp-2 cells grown on the slide were incubated with serum samples
diluted 1:64 for 30 min at 371C and then with fluorescein iso-
thiocyanate-conjugated goat anti-human g-globulin Abs (MBL) for
30 min at 371C. ELISA for antihistone and anti-ssDNA Ab was
performed as described previously (Sato et al, 1993). Briefly, 96-
well microtiter plates were coated with total histones (5 mg per mL;
Sigma-Aldrich) at 41C overnight. For anti-ssDNA Ab, wells were
pre-treated with 0.1% protamine sulfate (grade X; Sigma-Aldrich)
for 1 h at 201C. After rinsing, the plates were coated with calf
thymus ssDNA (1 mg per mL; Sigma-Aldrich) at 41C overnight.
ELISA was performed as described for anti-Cu/Zn SOD Ab ELISA.
Absorbance values greater than the meanþ 3SD of normal
controls were considered positive in this study. Rheumatoid factor
was measured using a latex agglutination slide test (Eiken, Tokyo,
Japan), according to the manufacturer’s protocol. Latex beads
coated with human g-globulin (50 mL) were incubated with 50 mL of
serum samples for 1 min at 201C. Rheumatoid factor was
considered to be present when agglutination of latex beads was
observed.
Statistical analysis Statistical analysis was performed using the
Mann–Whitney U test for determining the level of significance of
differences between sample means, Fisher’s exact probability test
for comparison of frequencies, and Bonferroni’s test for multiple
comparisons. Spearman’s rank correlation coefficient was used to
examine the relationship between two continuous variables. A p
value less than 0.05 was considered statistically significant.
DOI: 10.1111/j.0022-202X.2004.22333.x
Manuscript received July 25, 2003; revised September 18, 2003;
accepted for publication September 24, 2003
Address correspondence to: Dr Shinichi Sato, Department of Derma-
tology, Kanazawa University Graduate School of Medical Science, 13-1
Takaramachi, Kanazawa, Ishikawa 920-8641, Japan. Email: s-sato@
med.kanazawa-u.ac.jp
References
Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J
Med 292:344–348, 1975a
Bohan A, Peter JB: Polymyositis and dermatomyositis (second of two parts). N
Engl J Med 292:403–407, 1975b
Chojkier M, Houglum K, Solis-Herruzo J, Brenner DA: Stimulation of collagen
gene expression by ascorbic acid in cultured human fibroblasts. A role for
lipid peroxidation? J Biol Chem 264:16957–16962, 1989
Delanian S, Baillet F, Huart J, Lefaix JL, Maulard C, Housset M: Successful
treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide
dismutase: Clinical trial. Radiother Oncol 32:12–20, 1994
Delanian S, Martin M, Bravard A, Luccioni C, Lefaix JL: Cu/Zn superoxide
dismutase modulates phenotypic changes in cultured fibroblasts from
human skin with chronic radiotherapy damage. Radiother Oncol 58:325–
331, 2001
Falanga V, Medsger TA Jr, Reichlin M: Antinuclear and anti-single-stranded DNA
antibodies in morphea and generalized morphea. Arch Dermatol
123:350–353, 1987
Falanga V, Medsger TA Jr, Reichlin M, Rodnan GP: Linear scleroderma. Clinical
spectrum, prognosis, and laboratory abnormalities. Ann Intern Med
104:849–857, 1986
Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP: Tissue inhibitors of
metalloproteinases: Structure, regulation and biological functions. Eur J
Cell Biol 74:111–122, 1997
Gurney ME, Pu H, Chiu AY, et al: Motor neuron degeneration in mice that express
a human Cu,Zn superoxide dismutase mutation. Science 264:1772–1775,
1994
Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black C:
Immunocytochemical localization and serologic detection of transforming
growth factor b1: Association with type I procollagen and inflammatory
cell markers in diffuse and limited systemic sclerosis, morphea, and
Raynaud’s phenomenon. Arthritis Rheum 37:278–288, 1994
Jablonska S, Rodnan GP: Localized forms of scleroderma. Clin Rheum Dis
5:215–241, 1979
Komocsi A, Tovari E, Kovacs J, Czirjak L: Physical injury as a provoking factor in
three patients with scleroderma. Clin Exp Rheumatol 18:622–624, 2000
Kubo M, Ihn H, Yamane K, Tamaki K: Up-regulated expression of transforming
growth factor b receptors in dermal fibroblasts in skin sections from
patients with localized scleroderma. Arthritis Rheum 44:731–734, 2001
Lefaix JL, Delanian S, Leplat JJ, et al: Successful treatment of radiation-induced
fibrosis using Cu/Zn-SOD and Mn-SOD: An experimental study. Int J
Radiat Oncol Biol Phys 35:305–312, 1996
LeRoy EC, Krieg T, Black C, et al: Scleroderma (systemic sclerosis): Classifica-
tion, subsets, and pathogenesis. J Rheumatol 15:202–205, 1988
Marklund SL: Extracellular superoxide dismutase and other superoxide dis-
mutase isoenzymes in tissues from nine mammalian species. Biochem J
222:649–655, 1984
Mattila L, Airola K, Ahonen M, Hietarinta M, Black C, Saarialho-Kere U, Kahari
VM: Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA
expression in scleroderma skin fibroblasts. J Invest Dermatol 110:416–
421, 1998
Miyata M, Kogure A, Sato H, et al: Detection of antibodies to 65 KD heat shock
protein and to human superoxide dismutase in autoimmune hepatitis-
molecular mimicry between 65 KD heat shock protein and superoxide
dismutase. Clin Rheumatol 14:673–677, 1995
Noor R, Mittal S, Iqbal J: Superoxide dismutase—Applications and relevance to
human diseases. Med Sci Monit 8:RA210–215, 2002
Okano Y: Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis
Clin North Am 22:709–735, 1996
Reaume AG, Elliott JL, Hoffman EK, et al: Motor neurons in Cu/Zn superoxide
dismutase-deficient mice develop normally but exhibit enhanced cell
death after axonal injury. Nat Genet 13:43–47, 1996
Ritter K, Kuhl RJ, Semrau F, Eiffert H, Kratzin HD, Thomssen R: Manganese
superoxide dismutase as a target of autoantibodies in acute Epstein–Barr
virus infection. J Exp Med 180:1995–1998, 1994
Rosen DR, Siddique T, Patterson D, et al: Mutations in Cu/Zn superoxide
dismutase gene are associated with familial amyotrophic lateral sclerosis.
Nature 362:59–62, 1993
Ruiz IG, de la Torre P, Diaz T, Esteban E, Morillas JD, Munoz-Yague T, Solis-
Herruzo JA: Sp family of transcription factors is involved in iron-induced
collagen a1(I) gene expression. DNA Cell Biol 19:167–178, 2000
Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G, Gabrielli A:
Oxidative stress in scleroderma: Maintenance of scleroderma fibroblast
phenotype by the constitutive up-regulation of reactive oxygen species
generation through the NADPH oxidase complex pathway. Arthritis
Rheum 44:2653–2664, 2001
Sato S, Fujimoto M, Hasegawa M, Takehara K: Anti-phospholipid antibody in
localized scleroderma. Ann Rheum Dis 62:771–774, 2003
Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K: Antigen specificity of
antihistone antibodies in localized scleroderma. Arch Dermatol 130:
1273–1277, 1994a
Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K: Clinical characteristics
associated with antihistone antibodies in patients with localized sclero-
derma. J Am Acad Dermatol 31:567–571, 1994b
Sato S, Ihn H, Soma Y, et al: Antihistone antibodies in patients with localized
scleroderma. Arthritis Rheum 36:1137–1141, 1993
Semrau F, Kuhl RJ, Ritter S, Ritter K: Manganese superoxide dismutase (MnSOD)
and autoantibodies against MnSOD in acute viral infections. J Med Virol
55:161–167, 1998
Speer CP, Pabst MJ, Hedegaard HB, Rest RF, Johnston RB Jr: Enhanced release
of oxygen metabolites by monocyte-derived macrophages exposed to
proteolytic enzymes: Activity of neutrophil elastase and cathepsin G. J
Immunol 133:2151–2156, 1984
Subcommittee for Scleroderma Criteria of the American Rheumatism Association
Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for
the classification of systemic sclerosis (scleroderma). Arthritis Rheum
23:581–590, 1980
Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classification
of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277, 1982
Trattner A, Figer A, David M, Lurie H, Sandbank M: Circumscribed scleroderma
induced by postlumpectomy radiation therapy. Cancer 68:2131–2133,
1991
Varga J: Scleroderma and Smads: Dysfunctional Smad family dynamics
culminating in fibrosis. Arthritis Rheum 46:1703–1713, 2002
Vozenin-Brotons MC, Sivan V, Gault N, et al: Antifibrotic action of Cu/Zn SOD is
mediated by TGF-b1 repression and phenotypic reversion of myofibro-
blasts. Free Radic Biol Med 30:30–42, 2001
600 NAGAI ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Yamamoto T, Takagawa S, Katayama I, Mizushima Y, Nishioka K: Effect of
superoxide dismutase on bleomycin-induced dermal sclerosis: Implica-
tions for the treatment of systemic sclerosis. J Invest Dermatol 113:843–
847, 1999
Yamazaki C, Hoshino J, Hori Y, Sekiguchi T, Miyauchi S, Mizuno S, Horie K: Effect
of lecithinized-superoxide dismutase on the interstitial pneumonia model
induced by bleomycin in mice. Jpn J Pharmacol 75:97–100, 1997
Zelko IN, Mariani TJ, Folz RJ: Superoxide dismutase multigene family: A
comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD
(SOD3) gene structures, evolution, and expression. Free Radic Biol Med
33:337–349, 2002
Zhong Z, Froh M, Wheeler MD, Smutney O, Lehmann TG, Thurman RG: Viral
gene delivery of superoxide dismutase attenuates experimental choles-
tasis-induced liver fibrosis in the rat. Gene Ther 9:183–191, 2002
ANTI-SOD AUTOANTIBODY IN LOCALIZED SCLERODERMA 601122 : 3 MARCH 2004
